-
Mashup Score: 7Rad Onc Review | Radiation Oncology Review - 3 day(s) ago
Rad Onc Review is an actively updated collection of clinical trials which places evidence at the fingertips of busy practitioners. We aim to present topics in the most objective way possible through a participating audience in order to influence patient-centered care.
Source: www.radoncreview.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8
This phase 3 randomized clinical trial evaluates whether stereotactic body radiation therapy improves outcomes in patients with locally advanced hepatocellular carcinoma compared with sorafenib alone.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet-
This was a Phase III RCT of sorafenib +/- SBRT in Stage B/C HCC not amenable to resection, ablation, TACE. N=193. These were advanced tumors. In addition to not being eligible for other local therapies, 74% had MVI & median tumor size was 7.8 cm. 2/ https://t.co/2rCytpXaWn
-
-
Mashup Score: 8
This phase 3 randomized clinical trial evaluates whether stereotactic body radiation therapy improves outcomes in patients with locally advanced hepatocellular carcinoma compared with sorafenib alone.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet-
This was a Phase III RCT of sorafenib +/- SBRT in Stage B/C HCC not amenable to resection, ablation, TACE. N=193. These were advanced tumors. In addition to not being eligible for other local therapies, 74% had MVI & median tumor size was 7.8 cm. 2/ https://t.co/2rCytpXaWn
-
-
Mashup Score: 8
This phase 3 randomized clinical trial evaluates whether stereotactic body radiation therapy improves outcomes in patients with locally advanced hepatocellular carcinoma compared with sorafenib alone.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet-
This was a Phase III RCT of sorafenib +/- SBRT in Stage B/C HCC not amenable to resection, ablation, TACE. N=193. These were advanced tumors. In addition to not being eligible for other local therapies, 74% had MVI & median tumor size was 7.8 cm. 2/ https://t.co/2rCytpXaWn
-
-
Mashup Score: 8
This phase 3 randomized clinical trial evaluates whether stereotactic body radiation therapy improves outcomes in patients with locally advanced hepatocellular carcinoma compared with sorafenib alone.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet-
This was a Phase III RCT of sorafenib +/- SBRT in Stage B/C HCC not amenable to resection, ablation, TACE. N=193. These were advanced tumors. In addition to not being eligible for other local therapies, 74% had MVI & median tumor size was 7.8 cm. 2/ https://t.co/2rCytpXaWn
-
-
Mashup Score: 8
This phase 3 randomized clinical trial evaluates whether stereotactic body radiation therapy improves outcomes in patients with locally advanced hepatocellular carcinoma compared with sorafenib alone.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet-
This was a Phase III RCT of sorafenib +/- SBRT in Stage B/C HCC not amenable to resection, ablation, TACE. N=193. These were advanced tumors. In addition to not being eligible for other local therapies, 74% had MVI & median tumor size was 7.8 cm. 2/ https://t.co/2rCytpXaWn
-
-
Mashup Score: 8
This phase 3 randomized clinical trial evaluates whether stereotactic body radiation therapy improves outcomes in patients with locally advanced hepatocellular carcinoma compared with sorafenib alone.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet-
This was a Phase III RCT of sorafenib +/- SBRT in Stage B/C HCC not amenable to resection, ablation, TACE. N=193. These were advanced tumors. In addition to not being eligible for other local therapies, 74% had MVI & median tumor size was 7.8 cm. 2/ https://t.co/2rCytpXaWn
-
-
Mashup Score: 0
CT is the standard of care for patients presenting with unresectable advanced GBC but their prognosis remains poor. The value of consolidation CTRT after initial CT is uncertain. We therefore conducted a single centre open label randomised trial evaluating consolidation CTRT versus Observation after four cycles of CT in patients whose disease did not progress during CT (partial responders/stable disease).
Source: www.redjournal.orgCategories: General Medicine News, Hem/OncsTweet-
Link (someone told me to not put them in first tweet?) https://t.co/ygMgN4V7L2
-
-
Mashup Score: 11RP240233 — Cancer Prevention and Research Institute of Texas - 12 day(s) ago
Texans voted in 2007 to create the Cancer Prevention & Research Institute of Texas (CPRIT) and to invest $3 billion in the state’s unprecedented fight against cancer. On November 5, 2019, Texas voters overwhelmingly approved a constitutional amendment to continue CPRIT’s work and invest an additional $3 billion for finding and funding the best cancer research and prevention opportunities in the state. CPRIT is now a $6 billion, 20-year initiative – the largest state cancer research investment in the history of the United States and the second largest cancer research and prevention program in the world.
Source: cprit.texas.govCategories: General Medicine News, Hem/OncsTweet-
The study is supported by a @CPRITTexas grant. More info here! https://t.co/9VTcTncR5F
-
-
Mashup Score: 27Do We Have a Winner? Advocating for SBRT in HCC Management - 18 day(s) ago
“Yesterday’s home runs don’t win today’s games”Babe Ruth (attributed)
Source: www.ctro.scienceCategories: General Medicine News, Hem/OncsTweet-
Also did not even get into the local therapy debate here. Re: SBRT, this piece by @safaviaa & @ldawsonmd is great. https://t.co/1bGHu3gPp6
-
For anyone unaware of this great resource: https://t.co/VVfBMWE2wJ